Presentation is loading. Please wait.

Presentation is loading. Please wait.

TREATED RESPONDER 8 TREATED NONRESPDR 6 14 UNTREATED RESPONDER 1 UNTREATED NONRESPDR 11 12 9 17 26 PR (IHC)- PATIENTS (N=26) Ln(ER  ) mRNA level ≥ 12.47:

Published byProsper Nelson Modified over 8 years ago

Similar presentations

Presentation on theme: "TREATED RESPONDER 8 TREATED NONRESPDR 6 14 UNTREATED RESPONDER 1 UNTREATED NONRESPDR 11 12 9 17 26 PR (IHC)- PATIENTS (N=26) Ln(ER  ) mRNA level ≥ 12.47:"— Presentation transcript:

1 TREATED RESPONDER 8 TREATED NONRESPDR 6 14 UNTREATED RESPONDER 1 UNTREATED NONRESPDR 11 12 9 17 26 PR (IHC)- PATIENTS (N=26) Ln(ER  ) mRNA level ≥ 12.47: AUC =0.824, p=0.02 ER  mRNA positive negative TOTAL PRESENT ABSENT CLINICAL BENEFIT Sensitivity = 8/9 (89%) Specificity = 11/17 (65%) Positive Predictive Value = 8/14 (57%) TOTAL Ln(ER  ) mRNA > 12.47: 2040 6080 100 20 40 60 80 100 0 AUC=0.824 (.639, 1.00) P=0.02 100% - Specificity Sensitivity Supplemental Figure 3A

2 TREATED RESPONDER 7 TREATED NONRESPDR 5 12 UNTREATED RESPONDER 2 UNTREATED NONRESPDR 12 14 91726 BRCA1 mRNA positive negative TOTAL PRESENTABSENT CLINICAL BENEFIT Sensitivity = 7/9 (78%) Specificity = 12/17 (71%) Positive Predictive Value = 7/12 (64%) TOTAL Ln(BRCA-1) mRNA > 11.14: 0 20 40 60 80 100 20 40 60 80 100 AUC=0.817 (.629, 1.00) P=0.033 100% - Specificity Sensitivity PR (IHC)- PATIENTS (N=26) Ln(BRCA1) mRNA level ≥ 11.14: AUC= 0.817, p= 0.033 Supplemental Figure 3B

3 TREATED RESPONDER 7 TREATED NONRESPDR 0 7 UNTREATED RESPONDER 2 UNTREATED NONRESPDR 17 19 91726 PR (IHC)- PATIENTS (N=26) Ln(BRCA1 mRNA) ≥ 15.49-0.31 Ln(ER  mRNA level) Ln(BRCA1 mRNA) > 15.49 – 0.31 Ln(ER  mRNA): 0 2040 80 10060 20 40 60 80 100 AUC=0.902 (.757, 1.00) P=0.043 100% - Specificity Sensitivity ER  BRCA1 mRNA positive negative TOTAL PRESENTABSENT CLINICAL BENEFIT Sensitivity = 7/9 (78%) Specificity = 17/17 (100%) Positive Predictive Value = 7/7 (100%) TOTAL Supplemental Figure 3C

Download ppt "TREATED RESPONDER 8 TREATED NONRESPDR 6 14 UNTREATED RESPONDER 1 UNTREATED NONRESPDR 11 12 9 17 26 PR (IHC)- PATIENTS (N=26) Ln(ER  ) mRNA level ≥ 12.47:"

Similar presentations

Supplemental figure 1 ROS production in MM cell line (KMM1) treated with bortezomib and DCA. ROS production was marginally increased by DCA in combination.

Supplemental figure 1 ROS production in MM cell line (KMM1) treated with bortezomib and DCA. ROS production was marginally increased by DCA in combination.
IVD Validation and Regulation in Rx/Dx Combinations

IVD Validation and Regulation in Rx/Dx Combinations
Triple-Negative Breast Cancer

Triple-Negative Breast Cancer
C1q g/L C2 g/L C3 g/L C4 g/L A. B. C.D. E. Supplementary Figure 1 - Middleton et al. NR Supplementary Figure 1. Complement concentrations in CLL patient.

C1q g/L C2 g/L C3 g/L C4 g/L A. B. C.D. E. Supplementary Figure 1 - Middleton et al. NR Supplementary Figure 1. Complement concentrations in CLL patient.
Supplemental Figure 1 A No. at risk T3 530 483 304 185 50 T2 559 545 373 228 76 T1 540 532 375 208 64.

Supplemental Figure 1 A No. at risk T T T
Sino-Danish Breast Cancer Research Centre Beijing Genomic Institute, Shenzhen University of Copenhagen University of Århus University of Southern Denmark.

Sino-Danish Breast Cancer Research Centre Beijing Genomic Institute, Shenzhen University of Copenhagen University of Århus University of Southern Denmark.
Carolina Breast Cancer Study: Breast cancer subtypes and race Robert Millikan University of North Carolina Chapel Hill, NC.

Carolina Breast Cancer Study: Breast cancer subtypes and race Robert Millikan University of North Carolina Chapel Hill, NC.
P449. p450 Figure 15-1 p451 Figure 15-2 p453 Figure 15-2a p453.

P449. p450 Figure 15-1 p451 Figure 15-2 p453 Figure 15-2a p453.
Performance measures Morten Nielsen, CBS, BioCentrum, DTU.

Performance measures Morten Nielsen, CBS, BioCentrum, DTU.
Introduction to Biomedical Statistics. Signal Detection Theory What do we actually “detect” when we say we’ve detected something?

Introduction to Biomedical Statistics. Signal Detection Theory What do we actually “detect” when we say we’ve detected something?
P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.

P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.
Geonomics in Breast Cancer Decoding Human Genome Luis Barreras, M.D., FACP.

Geonomics in Breast Cancer Decoding Human Genome Luis Barreras, M.D., FACP.
Discordance in Hormone Receptor and HER2 Status in Breast Cancer during Tumor Progression Lindstrom LS et al. Proc SABCS 2010;Abstract S3-5.

Discordance in Hormone Receptor and HER2 Status in Breast Cancer during Tumor Progression Lindstrom LS et al. Proc SABCS 2010;Abstract S3-5.
Metastatic Breast Cancer: One Size Does Not Fit All Clifford Hudis, M.D. Chief, Breast Cancer Medicine Service MSKCC.

Metastatic Breast Cancer: One Size Does Not Fit All Clifford Hudis, M.D. Chief, Breast Cancer Medicine Service MSKCC.
Supplementary Figure 1. Supplementary Figure 2 All patients CharacteristicN% Median Age of patients 58 yrs ER Positive 40 69 Negative 18 31 PR Positive.

Supplementary Figure 1. Supplementary Figure 2 All patients CharacteristicN% Median Age of patients 58 yrs ER Positive Negative PR Positive.
Appendix Supplementary data (online only) to: Marleen Kok, Wilbert Zwart, Caroline Holm, Renske Fles, Michael Hauptmann, Laura J. Van ’t Veer, Lodewyk.

Appendix Supplementary data (online only) to: Marleen Kok, Wilbert Zwart, Caroline Holm, Renske Fles, Michael Hauptmann, Laura J. Van ’t Veer, Lodewyk.
The PCA3 Assay improves the prediction of initial biopsy outcome and may be indicative of prostate cancer aggressiveness de la Taille A, Irani J, Graefen.

The PCA3 Assay improves the prediction of initial biopsy outcome and may be indicative of prostate cancer aggressiveness de la Taille A, Irani J, Graefen.
Prognostic Value of Genomic Analysis After Neoadjuvant Chemotherapy for Breast Cancer Mayer EL et al. Proc SABCS 2010;Abstract P3-10-13.

Prognostic Value of Genomic Analysis After Neoadjuvant Chemotherapy for Breast Cancer Mayer EL et al. Proc SABCS 2010;Abstract P
Diagnostic Test Characteristics Professor Mobeen Iqbal Shifa College of Medicine.

Diagnostic Test Characteristics Professor Mobeen Iqbal Shifa College of Medicine.
Ab hg fe d c Supplementary Figure 1 Supplementary figure 1: Validation of the ERRα antibody used for immunohistochemical analysis. Control MCF7 breast.

Ab hg fe d c Supplementary Figure 1 Supplementary figure 1: Validation of the ERRα antibody used for immunohistochemical analysis. Control MCF7 breast.

Similar presentations

Ads by Google